

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/533,844
<i>(Use as many sheets as necessary)</i>				<i>Filing Date</i>	May 4, 2005
				<i>First Named Inventor</i>	Hagen, Frederick S.
				<i>Art Unit</i>	1649
				<i>Examiner Name</i>	Olga N. Chernyshev
Sheet	1	of	5	<i>Attorney Docket Number</i>	017881-001010US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AA	US-5,604,102		02-18-1997	McConlogue et al.	
AB	US-5,658,754		08-19-1997	Kawasaki	
AC	US-6,153,380		11-28-2000	Nolan et al.	
AD	US-6,175,057		01-16-2001	Mucke et al.	
AE	US-6,267,962		07-31-2001	Hart et al.	
AF	US-6,365,634		04-02-2002	Russell et al.	
AG	US-6,420,110		07-16-2002	Gyuris et al.	
AH	US-6,440,698		08-27-2002	Gurney et al.	
AI	US-2002/0127564		09-12-2002	Nolan	
AJ	US-2006/0275833		12-07-2006	Hagen	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴				
AK	PCT	WO 98/21589	A1	05-22-1998	University of Pennsylvania		<input type="checkbox"/>
AL	PCT	WO 98/9483	A1	09-11-1998	Ventana Genetics, Inc.		<input type="checkbox"/>
AM	PCT	WO 99/24617	A1	05-20-1999	Ventana Genetics, Inc.		<input type="checkbox"/>
AN	PCT	WO 01/49097	A2	07-12-2001	Bienkowski et al.		<input type="checkbox"/>
AO	PCT	WO 03/57165	A2	07-17-2003	The Rockefeller University		<input type="checkbox"/>
AP	PCT	WO 04/18997	A2	03-04-2004	Neurogenetics, Inc.		<input type="checkbox"/>
AQ	PCT	WO 04/42074	A2	05-21-2004	Icogen Corp.		<input type="checkbox"/>

Examiner Signature		Date Considered
--------------------	--	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
				<i>Application Number</i>	10/533,844
				<i>Filing Date</i>	May 4, 2005
				<i>First Named Inventor</i>	Hagen, Frederick S.
				<i>Art Unit</i>	1649
				<i>Examiner Name</i>	Olga N. Chemyshev
Sheet	2	of	5	<i>Attorney Docket Number</i>	017881-001010US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	AR	BROWN, "Metal-recognition by repeating polypeptides," <i>Nat. Biotechnol.</i> 15:269-272 (1997).			<input type="checkbox"/>
	AS	CEDAZO-MINGUEZ <i>et al.</i> , "Nicergoline stimulates protein kinase C mediated α -secretase processing of the amyloid precursor protein in cultured human neuroblastoma SH-SY5Y cells," <i>Neurochem. Int.</i> 35:307-315 (1999).			<input type="checkbox"/>
	AT	CULL <i>et al.</i> , "Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor," <i>Proc. Natl. Acad. Sci. USA</i> 89:1865-1869 (1992).			<input type="checkbox"/>
	AU	DE STROOPER <i>et al.</i> , "Exchanging the extracellular domain of amyloid precursor protein for horseradish peroxidase does not interfere with α -secretase cleavage of the β -amyloid region, but randomizes secretion in Madin-Darby canine kidney cells," <i>J. Biol. Chem.</i> 270:30310-30314 (1995).			<input type="checkbox"/>
	AV	FIELDS and SONG, "A novel genetic system to detect protein-protein interactions," <i>Nature</i> 340:245-246 (1989).			<input type="checkbox"/>
	AW	GAMES <i>et al.</i> , "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein," <i>Nature</i> 373:523-527 (1995).			<input type="checkbox"/>
	AX	GILCHRIST <i>et al.</i> , "Use of peptides-on-plasmids combinatorial library to identify high-affinity peptides that bind rhodopsin," <i>Methods Enzymol.</i> 315:388-404 (2000).			<input type="checkbox"/>
	AY	GOTZ <i>et al.</i> , "Formation of neurofibrillary tangles in P301L tau transgenic mice induced by A β 42 fibrils," <i>Science</i> 293:1491-1495 (2001).			<input type="checkbox"/>
	AZ	HARTLEY <i>et al.</i> , "Protofibrillar intermediates of amyloid β -protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons," <i>J. Neurosci.</i> 19:8876-8884 (1999).			<input type="checkbox"/>
	BA	HSIAO <i>et al.</i> , "Correlative memory deficits, A β elevation, and amyloid plaques in transgenic mice," <i>Science</i> 274:99-102 (1996).			<input type="checkbox"/>

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/533,844
(Use as many sheets as necessary)				<i>Filing Date</i>	May 4, 2005
				<i>First Named Inventor</i>	Hagen, Frederick S.
				<i>Art Unit</i>	1649
				<i>Examiner Name</i>	Olga N. Chernyshew
Sheet	3	of	5	<i>Attorney Docket Number</i>	017881-001010US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	BB	KANG <i>et al.</i> , "The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor," <i>Nature</i> 325:733-736 (1987).			<input type="checkbox"/>
	BC	KAWARABAYASHI <i>et al.</i> , "Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease," <i>J. Neurosci.</i> 21:372-381 (2001).			<input type="checkbox"/>
	BD	KINSELLA <i>et al.</i> , "Retrovirally delivered random cyclic peptide libraries yield inhibitors of interleukin-4 signaling in human B cells," <i>J. Biol. Chem.</i> 277:37512-37518 (2002).			<input type="checkbox"/>
	BE	KJAERGAARD <i>et al.</i> , "Novel Zn ²⁺ -chelating peptides selected from a fimbria-displayed random peptide library," <i>Appl. Environ. Microbiol.</i> 67:5467-5473 (2001).			<input type="checkbox"/>
	BF	LABEAN and KAUFFMAN, "Design of synthetic gene libraries encoding random sequence proteins with desired ensemble characteristics," <i>Protein Sci.</i> 2:1249-1254 (1993).			<input type="checkbox"/>
	BG	LAMMICH <i>et al.</i> , "Constitutive and regulated α -secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease," <i>Proc. Natl. Acad. Sci. USA</i> 96:3922-3927 (1999).			<input type="checkbox"/>
	BH	LOPEZ-PEREZ <i>et al.</i> , "Proprotein convertase activity contributes to the processing of the Alzheimer's β -amyloid precursor protein in human cells: evidence for a role of the prohormone convertase PC7 in the constitutive α -secretase pathway," <i>J. Neurochem.</i> 73:2056-2062 (1999).			<input type="checkbox"/>
	BI	LU <i>et al.</i> , "Expression of thioredoxin random peptide libraries on the <i>Escherichia coli</i> cell surface as functional fusions to flagellin: a system designed for exploring protein-protein interactions," <i>Biotechnology</i> 13:366-372 (1995).			<input type="checkbox"/>
	BJ	MAZUR-KOLECKA <i>et al.</i> , "Accumulation of Alzheimer amyloid-peptide in cultured myocytes is enhanced by serum and reduced by cerebrospinal fluid," <i>J. Neuropathol. Exp. Neurol.</i> 56(3):263-272, Abstract only, (1997).			<input type="checkbox"/>
	BK	MILLER <i>et al.</i> , "Use of retroviral vectors for gene transfer and expression," <i>Methods Enzymol.</i> 217:581-599 (1993).			<input type="checkbox"/>
	BL	MULLAN <i>et al.</i> , "A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β -amyloid," <i>Nat. Genet.</i> 1:345-347 (1992).			<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/533,844
<i>(Use as many sheets as necessary)</i>				<i>Filing Date</i>	May 4, 2005
				<i>First Named Inventor</i>	Hagen, Frederick S.
				<i>Art Unit</i>	1649
				<i>Examiner Name</i>	Olga N. Chernyshev
Sheet	4	of	5	<i>Attorney Docket Number</i>	017881-001010US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	BM	MURTHY, "Characterization of the interleukin 3 receptor," <i>Exp. Hematol.</i> 18(1):11-17 (1990).			<input type="checkbox"/>
	BN	NILSBERTH <i>et al.</i> , "The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced A β protofibril formation," <i>Nat. Neurosci.</i> 4:887-893 (2001).			<input type="checkbox"/>
	BO	NILSSON <i>et al.</i> , "a-1-antichymotrypsin promotes β -sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease," <i>J. Neurosci.</i> 21:1444-1451 (2001).			<input type="checkbox"/>
	BP	NORMAN <i>et al.</i> , "Genetic selection of peptide inhibitors of biological pathways," <i>Science</i> 285:591-595 (1999).			<input type="checkbox"/>
	BQ	PARVATHY <i>et al.</i> , "Alzheimer's amyloid precursor protein α -secretase is inhibited by hydroxamic acid-based zinc metalloprotease inhibitors: similarities to the angiotensin converting enzyme secretase," <i>Biochemistry</i> 37:1680-1685 (1998).			<input type="checkbox"/>
	BR	PONCET, "CD24, a glycosylphosphatidylinositol-anchored molecule is transiently expressed during the development of human central nervous system and is a marker of human neural cell lineage tumors," <i>Acta. Neuropathol.</i> 91(4):400-408, Abstract only, (1996).			<input type="checkbox"/>
	BS	RIAN <i>et al.</i> , "A signal sequence trap based on cell enrichment using anti-CD19 antibody coated magnetic beads," <i>Scand. J. Immunol.</i> 54:280-284 (2001).			<input type="checkbox"/>
	BT	SCOTT and SMITH, "Searching for peptide ligands with an epitope library," <i>Science</i> 249:386-390 (1990).			<input type="checkbox"/>
	BU	SELKOE, "Alzheimer's disease: genes, proteins, and therapy," <i>Physiol. Rev.</i> 81:741-766 (2001).			<input type="checkbox"/>
	BV	SELKOE, "Alzheimer's disease is a synaptic failure," <i>Science</i> 298:789-791 (2002).			<input type="checkbox"/>
	BW	SINHA, <i>et al.</i> , "Purification and cloning of amyloid precursor protein β -secretase from human brain," <i>Nature</i> 402:537-540 (1999).			<input type="checkbox"/>
	BX	SISODIA, " β -amyloid precursor protein cleavage by a membrane-bound protease," <i>Proc. Natl. Acad. Sci. USA</i> 89:6075-6079 (1992).			<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Examiner's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/533,844
<i>(Use as many sheets as necessary)</i>				<i>Filing Date</i>	May 4, 2005
				<i>First Named Inventor</i>	Hagen, Frederick S.
				<i>Art Unit</i>	1649
				<i>Examiner Name</i>	Olga N. Chernyshev
Sheet	5	of	5	<i>Attorney Docket Number</i>	017881-001010US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	BY	STEINER and HAASS, "Intramembrane proteolysis by presenilins," <i>Nat. Rev. Mol. Cell. Biol.</i> 1:217-224 (2000). <input type="checkbox"/>		
	BZ	WESTERMAN <i>et al.</i> , "The relationship between A β and memory in the Tg2576 mouse model of Alzheimer's disease," <i>J. Neurosci.</i> 22:1858-1867 (2002). <input type="checkbox"/>		
	CA	WILSON <i>et al.</i> , "The use of mRNA display to select high-affinity protein-binding peptides," <i>PNAS</i> 98:3750-3755 (2001). <input type="checkbox"/>		

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.